Novartis Ag Stock Current Valuation
NVSEF Stock | USD 96.00 0.89 0.94% |
Valuation analysis of Novartis AG helps investors to measure Novartis' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Novartis' price fluctuation is very steady at this time. Calculation of the real value of Novartis AG is based on 3 months time horizon. Increasing Novartis' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Novartis AG is useful when determining the fair value of the Novartis pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Novartis. Since Novartis is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novartis Pink Sheet. However, Novartis' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 96.0 | Real 89.07 | Hype 96.0 | Naive 96.39 |
The real value of Novartis Pink Sheet, also known as its intrinsic value, is the underlying worth of Novartis AG Company, which is reflected in its stock price. It is based on Novartis' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Novartis' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novartis' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novartis AG helps investors to forecast how Novartis pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novartis more accurately as focusing exclusively on Novartis' fundamentals will not take into account other important factors: Novartis AG Company Current Valuation Analysis
Novartis' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Novartis Current Valuation | 207.39 B |
Most of Novartis' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition |
In accordance with the recently published financial statements, Novartis AG has a Current Valuation of 207.39 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current valuation for all United States stocks is significantly lower than that of the firm.
Novartis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in current valuation category among related companies.
Novartis Fundamentals
Return On Equity | 0.11 | |||
Return On Asset | 0.0645 | |||
Profit Margin | 0.13 % | |||
Operating Margin | 0.25 % | |||
Current Valuation | 207.39 B | |||
Shares Outstanding | 2.12 B | |||
Shares Owned By Insiders | 3.74 % | |||
Shares Owned By Institutions | 33.74 % | |||
Price To Earning | 25.00 X | |||
Price To Book | 3.22 X | |||
Price To Sales | 3.82 X | |||
Revenue | 51.83 B | |||
Gross Profit | 36.74 B | |||
EBITDA | 16.39 B | |||
Net Income | 6.96 B | |||
Cash And Equivalents | 19.1 B | |||
Cash Per Share | 8.81 X | |||
Total Debt | 20.24 B | |||
Debt To Equity | 0.47 % | |||
Current Ratio | 1.31 X | |||
Book Value Per Share | 28.00 X | |||
Cash Flow From Operations | 14.24 B | |||
Earnings Per Share | 3.17 X | |||
Price To Earnings To Growth | 5.67 X | |||
Number Of Employees | 102 K | |||
Beta | 0.47 | |||
Market Capitalization | 183.29 B | |||
Total Asset | 117.45 B | |||
Working Capital | 1.28 B | |||
Current Asset | 25.88 B | |||
Current Liabilities | 24.6 B | |||
Z Score | 5.4 | |||
Annual Yield | 0.04 % | |||
Five Year Return | 3.29 % | |||
Net Asset | 117.45 B | |||
Last Dividend Paid | 3.46 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Novartis Pink Sheet analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |